Education
About Us
Working with TipRanks
Follow Us
Ensysce Biosciences (ENSC)
NASDAQ:ENSC
ENSC Stock Chart & Stats
$1.64
-$0.28(-3.41%)
At close: 4:00 PM EST
$1.64
-$0.28(-3.41%)
Day’s Range― - ―
52-Week Range$1.53 - $10.96
Previous CloseN/A
Volume52.20K
Average Volume (3M)89.63K
Market Cap
$6.27M
Enterprise Value$5.20M
Total Cash (Recent Filing)$1.67M
Total Debt (Recent Filing)$364.07K
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding3,541,262
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)3.83
Price to Sales (P/S)2.73
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit-1.24
Enterprise Value/Ebitda-2.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $1.52 and its highest was $10.96 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $6.27M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is Mar 26, 2026 which is in 113 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on Nov 14, 2025. The company reported -$1.292 earnings per share for the quarter, missing the consensus estimate of -$0.825 by -$0.467.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 3,541,262 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$1.292 in its last earnings report, missing expectations of -$0.825. Following the earnings report the stock price went down -0.483%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
Company Description
Ensysce Biosciences
Ensysce Biosciences (ENSC) is a biotechnology company focused on developing innovative solutions for pain management and the treatment of opioid use disorders. The company operates in the pharmaceutical sector and is dedicated to addressing the opioid crisis through its proprietary technology platforms, including TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance). These platforms are designed to improve the safety and efficacy of prescription drugs, reducing the potential for abuse and addiction.
Technical Analysis
NovaBay Pharma
―
Galmed Pharmaceuticals
―
Cyclerion Therapeutics
―
Silo Pharma
―
Alzamend Neuro
―
Ownership Overview
―
Insiders
0.37% Mutual Funds
8.60% Other Institutional Investors
90.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---